FrancophonIA/ELRC3.0 huggingface dataset:
English: SUN MON TUE WED THU FRI SAT MON TUE WED THU FRI SAT SUN TUE WED THU FRI SAT SUN MON WED THU FRI SAT SUN MON TUE THU FRI SAT SUN MON TUE WED FRI SAT SUN MON TUE WED THU SAT SUN MON TUE WED THU FRI
Slovenian: NED PON TOR SRE ČET PET SOB PON TOR SRE ČET PET SOB NED TOR SRE ČET PET SOB NED PON SRE ČET PET SOB NED PON TOR ČET PET SOB NED PON TOR SRE PET SOB NED PON TOR SRE ČET SOB NED PON TOR SRE ČET PET
English: This will help you to determine when the baby will be due.
Slovenian: Tako boste namreč lažje izračunali rok poroda.
English: Poly(vinyl alcohol) (E1203), titanium dioxide (E171), macrogol 3350 and talc (E553b) Tablet coat (yellow placebo film-coated tablets):
Slovenian: Obloga tablete (bele aktivne filmsko obložene tablete): polivinil alkohol (E1203), titanov dioksid (E 171), makrogol 3350 in smukec (E553b) Obloga tablete (rumene placebo filmsko obložene tablete): polivinil alkohol (E1203), titanov dioksid (E 171), makrogol 3350, smukec (E553b), rumeni železov oksid (E 172) in črni železov oksid (E 172)
English: Stroke
Slovenian: Dojenje
English: You do not need to use extra precautions if you have taken your tablets correctly in the 7 days prior to the missed tablet.
Slovenian: Če ste pravilno jemali tablete v 7 dneh pred pozabljeno tableto, niso potrebni dodatni ukrepi.
English: How to store Zoely
Slovenian: Shranjevanje zdravila Zoely
English: It may harm them,
Slovenian: - občutek slabosti (navzea),
English: They may be taken with or without food.
Slovenian: Lahko se jemljejo skupaj s hrano ali brez nje.
English: If you are sick
Slovenian: Če ste bolni
English: Then continue taking your capsules at regular times as usual.
Slovenian: Nato kapsule jemljite redno, kot običajno.
English: (11.1, NE)
Slovenian: (11,1, neovrednoteno)
English: These data show that the efficacy of the combination would be lower in these patients.
Slovenian: Ti podatki kažejo, da bi bila učinkovitost kombinacije pri teh bolnikih nižja.
English: Partial reversibility of these findings was noted after a 4-week recovery period.
Slovenian: Delna reverzibilnost teh odkritij je bila zabeležena po štiritedenskem obdobju okrevanja.
English: If possible, show them this leaflet and the medicine package.
Slovenian: Če je mogoče, jim pokažite to navodilo in ovojnino zdravila.
English: All events were Grade 1-2.
Slovenian: Vsi dogodki so bili 1.-2. stopnje.
English: Therefore, the potential need for dose adjustment cannot be determined.
Slovenian: Zato morebitne potrebe po prilagajanju odmerka ni mogoče ugotoviti.
English: PFS as assessed by investigators (investigator assessment) was a supportive analysis.
Slovenian: PFS, kot so ga ocenili raziskovalci (ocenjevanje raziskovalcev), je bil podporna analiza.
English: Nominal p-value
Slovenian: Nominalna p-vrednost
English: In urine, 1.8% of the radioactivity was excreted as encorafenib.
Slovenian: V urinu je bilo 1,8 % radioaktivnosti izločene kot enkorafenib.
English: Braftovi is not recommended for children and adolescents under 18 years of age.
Slovenian: Zdravilo Braftovi se ne priporoča za otroke in mladostnike, mlajše od 18 let.
English: Other contributing factors included diabetes and hypertension.
Slovenian: Drugi spremljevalni dejavniki so vključevali diabetes in hipertenzijo.
English: Both patients experienced Grade 3 events.
Slovenian: Pri obeh bolnikih so se pojavili dogodki 3. stopnje.
English: The events were reversible, and no event led to treatment discontinuation.
Slovenian: Dogodki so bili reverzibilni in nobeden ni privedel do prenehanja zdravljenja.
English: No event required discontinuation, dose modification or interruption.
Slovenian: Nobeden izmed dogodkov ni zahteval prenehanja, spremembe odmerka ali prekinitev.
English: This medicine has not been studied in this age group.
Slovenian: To zdravilo ni bilo preskušeno za to starostno skupino.
English: The length of the capsule is approximately 23 mm.
Slovenian: Dolžina kapsule je približno 23 mm.
English: The safety and efficacy of encorafenib have not yet been established in children and adolescents.
Slovenian: Varnost in učinkovitost enkorafeniba pri otrocih in mladostnikih še ni bila dokazana.
English: Patients should be assessed at each visit for symptoms of new or worsening visual disturbance.
Slovenian: Bolnike je treba ob vsakem obisku pregledati za simptome novih ali poslabšanih motenj vida.
English: Encorafenib was not genotoxic.
Slovenian: Enkorafenib ni bil genotoksičen.
English: All events occurred in the setting of new or progressive brain metastases.
Slovenian: Do vseh dogodkov je prišlo v primeru novih ali razvitih metastaz v možganih.
English: Date of first authorisation: 20 September 2018
Slovenian: Datum prve odobritve: 20. september 2018
English: This translates into a 55% increase of the unbound encorafenib exposure.
Slovenian: To pomeni 55 % povečanje izpostavljenosti nevezanega enkorafeniba.
English: Tell your doctor immediately if you have any of the following serious side effects, either for the first time or if they get worse (see also section 2):
Slovenian: Nemudoma obvestite zdravnika, če imate katerega izmed naslednjih resnih neželenih učinkov - če do njih pride prvič ali če se stanje poslabša (glejte tudi poglavje 2):
English: As the clinical relevance of this is unknown, male patients should be informed of the potential risk for impaired spermatogenesis.
Slovenian: Ker je klinična pomembnost tega neznana, je treba bolnike moškega spola obvestiti o morebitnem tveganju za motnje spermatogeneze.
English: Braftovi can be taken with food or between meals.
Slovenian: Zdravilo Braftovi se lahko jemlje skupaj s hrano ali med obroki.
English: The capsules are to be swallowed whole with water.
Slovenian: Kapsule je treba pogoltniti cele z vodo.
English: Prior treatment with BRAF/ MEK inhibitors was not allowed.
Slovenian: Predhodno zdravljenje z inhibitorji BRAF/MEK ni bilo dovoljeno.
English: The efficacy results based on investigator assessment were consistent with the independent central assessment.
Slovenian: Rezultati učinkovitosti glede na ocene raziskovalcev so se ujemali z rezultati neodvisnega centralnega ocenjevanja.
English: Drink plenty of fluids during treatment.
Slovenian: Med zdravljenjem pijte veliko tekočin.
English: Genital examinations (for women) and anal examinations are also recommended before and at the end of your treatment.
Slovenian: Pregledi spolovil (za ženske) in analni pregledi se prav tako priporočajo pred in na koncu zdravljenja.
English: Encorafenib is moderately (86.1%) bound to human plasma proteins in vitro.
Slovenian: Enkorafenib je zmerno (86,1 %) vezan na proteine človeške plazme in vitro.
English: Treatment continued until disease progression or unacceptable toxicity.
Slovenian: Zdravljenje se je nadaljevalo do napredovanja bolezni ali nesprejemljive toksičnosti.
English: Encorafenib is a potent and highly selective ATP-competitive small molecule RAF kinase inhibitor.
Slovenian: Enkorafenib je močen in visoko selektiven malomolekulski ATP-kompetitivni inhibitor kinaze RAF.
English: QTc Prolongation
Slovenian: Podaljšanje QTc
English: Similar results were observed per Investigator assessment.
Slovenian: Podobni rezultati so se pokazali tudi pri posameznih ocenah raziskovalcev.
English: Dose modifications in case of adverse reactions are provided below and in Table 2.
Slovenian: Prilagoditve odmerka v primeru neželenih učinkov so navedene spodaj in v preglednici 2.
English: There are limited data for dose reduction to 100mg once daily.
Slovenian: Za zmanjšanje odmerka na 100 mg enkrat dnevno so na voljo omejeni podatki.
English: Renal failure was generally reversible with dose interruption, rehydration and other general supportive measures.
Slovenian: Okvara ledvic je bila večinoma reverzibilna s prekinitvijo jemanja odmerkov, rehidracijo in drugimi splošnimi podpornimi ukrepi.
English: Enrolment in Part 2 started after all Part 1 patients were randomised.
Slovenian: Vključevanje v 2. del se je začelo, ko so bili vsi bolniki iz 1. dela randomizirani.
English: Table 5 and Figure 1 summarize the PFS and other efficacy results based on central review of the data by a blinded independent radiology committee.
Slovenian: preglednici 5 in na sliki 1 je povzetek vrednosti PFS in drugih rezultatov učinkovitosti glede na centralni pregled podatkov, ki ga je izvedel slepi neodvisni radiološki odbor.
English: After oral administration, encorafenib is rapidly absorbed with a median Tmax of 1.5 to 2 hours.
Slovenian: Po peroralni uporabi se enkorafenib zelo hitro absorbira z mediano Tmax od 1,5 do 2 uri.
English: In the 13-week study, partial reversibility was noted at the highest dose level (60 mg/kg/d).
Slovenian: V 13-tedenski študiji je bila opažena delna reverzibilnost ob najvišji ravni odmerka (60 mg/kg/d).
English: Cut-off date: 19 May 2016
Slovenian: Končni datum: 19. maj 2016
English: A decision must be made whether to discontinue breast-feeding or to discontinue encorafenib therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother.
Slovenian: Odločiti se je treba, ali naj se prekine dojenje ali zdravljenje z enkorafenibom, pri čemer je treba upoštevati koristi dojenja za otroka in koristi zdravljenja za mater.
English: There are insufficient data to evaluate potential differences in the exposure of encorafenib by race or ethnicity.
Slovenian: Rasa Na voljo ni dovolj podatkov, da bi se ocenile morebitne razlike v izpostavljenosti enkorafeniba glede na rasno ali etnično pripadnost.
English: a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03
Slovenian: različica 4.03 (National Cancer Institute Common Terminology Criteria for Adverse Events; NCI CTCAE)
English: The predominant biotransformation reaction of encorafenib was N-dealkylation.
Slovenian: Predominantna biotransformacijska reakcija enkorafeniba je N-dealkilacija.
English: It is not known if Braftovi passes into breast milk.
Slovenian: Ni znano, ali zdravilo Braftovi prehaja v materino mleko.
English: Take the next dose as scheduled.
Slovenian: Naslednji odmerek vzemite po običajnem urniku.
English: The safety of encorafenib in combination with binimetinib has not been established in patients with a baseline LVEF that is either below 50% or below the institutional lower limits of normal.
Slovenian: Varnosti enkorafeniba v kombinaciji z binimetinibom niso dokazali pri bolnikih z izhodiščno vrednostjo LVEF, ki je ali pod 50 % ali pod institucionalnimi spodnjimi mejami normalne vrednosti.
English: Given the small magnitude of these changes and high variability, these are unlikely to be clinically meaningful, and no dose adjustments are needed for elderly patients.
Slovenian: Zaradi manjše magnitude teh sprememb in visoke variabilnosti je malo verjetno, da je ta podatek klinično pomemben, zato za starejše bolnike prilagoditev odmerka ni potrebna.
English: The NOAEL for the 13-week study was at 14- to 32-times human therapeutic exposures.
Slovenian: NOAEL za 13-tedensko študijo je bil 14- do 32-krat višji od terapevtskih odmerkov pri ljudeh.
English: There is no specific treatment for overdose.
Slovenian: Za preveliko odmerjanje ni posebnega zdravljenja.
English: Adverse reactions are listed below by MedDRA body system organ class and the following frequency convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Slovenian: Neželeni učinki so navedeni spodaj po MedDRA podatkovni bazi glede na organske sisteme in pogostnost: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
English: CI=Confidence interval; CR=Complete Response; DCR=Disease Control Rate (CR+PR+SD+Non-CR/Non-PD; Non-CR/Non-PD applies only to patients without a target lesion who did not achieve CR or have PD); HR=hazard ratio; NE=Not estimable; PFS=progression-free survival; PR=Partial response; SD=stable disease.
Slovenian: IZ=interval zaupanja; CR = skupni odziv; DCR = stopnja nadzora bolezni (CR + PR + SD + brez CR/brez PD; brez CR/brez PD velja samo za bolnike brez ciljne lezije, ki niso dosegli CR ali ki nimajo progresivne bolezni (PD)); HR = razmerje tveganja; PFS = preživetje brez napredovanja; PR = delni odziv; SD = stabilna bolezen.
English: The encorafenib dissociation half-life was >30 hours and resulted in prolonged pERK inhibition.
Slovenian: Razpolovna doba disociacije enkorafeniba je bila > 30 ur in je omogočila podaljšano zaviranje pERK.
English: The data suggest that hepatic uptake transporters are not involved in encorafenib distribution into primary human hepatocytes.
Slovenian: Ti podatki nakazujejo, da jetrni prenašalci privzema niso vključeni v distribucijo enkorafeniba v človeške primarne hepatocite.
English: In the small group of patients aged ≥75 years (n=15), patients were more likely to experience serious adverse events and adverse events leading to discontinuation of treatment.
Slovenian: V majhni skupini bolnikov, starih 75 let ali več (n = 15), je bila večja verjetnost za pojav resnih neželenih dogodkov in neželenih dogodkov, zaradi katerih je prišlo do prenehanja zdravljenja.
English: The inter-subject variability (CV%) of AUC is ranged from 12.3% to 68.9%.
Slovenian: Variabilnost med udeleženci (CV %) za AUC je v območju od 12,3 % do 68,9 %.
English: What you need to know before you take Braftovi 3.
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Braftovi 3.
English: In addition, encorafenib may inhibit P-gp in the gut and BCRP at the expected clinical concentrations.
Slovenian: Poleg tega enkorafenib lahko zavira P-gp v črevesju in BCRP v pričakovanih kliničnih koncentracijah.
English: Skin papilloma* Melanocytic nevus
Slovenian: Kožni papilom* Melanocitni nevus
English: Model based predictions indicate that the effect of posaconazole after repeated administrations could be similar for AUC (3-fold increase) and slightly greater for Cmax (2.7-fold increase).
Slovenian: Napovedi na podlagi modela kažejo, da bi učinek posakonazola po ponovljenih aplikacijah lahko bil podoben za AUC (3-kratno povečanje) in nekoliko večji za Cmax (2,7-kratno povečanje).
English: Your doctor will examine your eyes for any problems with your sight while you are taking Braftovi.
Slovenian: Zdravnik vam bo pregledal oči za kakršne koli težave z vidom med jemanjem zdravila Braftovi.
English: If symptoms of new or worsening visual disturbances including diminished central vision, blurred vision or loss of vision are identified, a prompt ophthalmologic examination is recommended.
Slovenian: Če so identificirani simptomi novih ali poslabšanih motenj vida, ki vključujejo zmanjšan centralni vid, zamegljen vid ali izgubo vida, se priporoča takojšen oftalmološki pregled.
English: If you get serious side effects (such as heart, eye or bleeding problems) your doctor may lower the dose or stop treatment temporarily or permanently.
Slovenian: Če pride do resnih neželenih učinkov (kot so težave s srcem, očmi ali krvavitve), vam zdravnik lahko zmanjša odmerek oz. začasno ali dokončno prekine zdravljenje.
English: Collectively, these data indicate that encorafenib has a risk of phototoxic potential and minimal risk for sensitization at therapeutic doses in patients.
Slovenian: Skupaj ti podatki kažejo, da enkorafenib predstavlja tveganje za blag fototoksični potencial in minimalno tveganje za preobčutljivost pri terapevtskih odmerkih pri bolnikih.
English: Number of events (progressive disease) (%)
Slovenian: Število dogodkov (progresivna bolezen) (%)
English: Encorafenib is not recommended during pregnancy and in women of childbearing potential not using contraception.
Slovenian: Enkorafenib se ne priporoča med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo kontracepcije.
English: Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Slovenian: V vsaki skupini pogostnosti so neželeni učinki razvrščeni padajoče glede na resnost.
English: Braftovi with food and drink
Slovenian: Zdravilo Braftovi skupaj s hrano in pijačo
English: A small decrease in CL/F (≤5%) was predicted for patients with mild and moderate renal impairment, which is unlikely to be clinically relevant.
Slovenian: Manjše zmanjšanje CL/F (≤ 5 %) je predvideno za bolnike z milejšo in zmerno okvaro jeter, ki pa je malo verjetno klinično relevantno.
English: Cardiac Electrophysiology
Slovenian: Kardiološka elektrofiziologija
English: Dermatitis acneiform* PPES
Slovenian: Akneiformni dermatitis* PPES
English: Patients were permitted to receive prior adjuvant therapy and one prior line of immunotherapy for unresectable locally advanced or metastatic disease.
Slovenian: Bolniki so pred tem lahko prejemali adjuvantno zdravljenje in eno predhodno imunoterapijo za neresektabilno lokalno napredujočo ali metastatsko bolezen.
English: Patients should be instructed to immediately inform their physicians if new skin lesions develop.
Slovenian: Bolnikom je treba naročiti, naj svojega zdravnika takoj obvestijo o pojavu kakršnih koli lezij na koži.
English: Encorafenib potentially inhibits a number of transporters.
Slovenian: Encorafenib potencialno zavira nekatere prenašalce.
English: Patients should be advised not to drive or use machines if they experience visual disturbances or any other adverse reactions that may affect their ability to drive and use machines (see sections 4.4 and 4.8).
Slovenian: Bolnikom je treba svetovati, naj ne vozijo ali upravljajo strojev, če zaznajo motnje vida ali katere koli druge neželene učinke, ki bi lahko vplivali na njihovo sposobnost vožnje in upravljanja strojev (glejte poglavji 4.4. in 4.8).
English: Swallow the capsules whole with water.
Slovenian: Kapsule pogoltnite cele z vodo.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with encorafenib in one or more subsets of the paediatric population in melanoma (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z enkorafenibom za eno ali več podskupin pediatrične populacije z melanomom (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: Adverse reactions reported by this patient were Grade 1 events of nausea, vomiting and blurred vision; all subsequently resolved.
Slovenian: Neželeni učinki, o katerih je poročal ta bolnik, so vključevali dogodke 1. stopnje slabosti, bruhanja in zamegljenega vida, ki so vsi pozneje prenehali.
English: Some medicines may affect how Braftovi works or make it more likely that you will have side effects.
Slovenian: Nekatera zdravila lahko vplivajo na delovanje zdravila Braftovi ali pa zaradi njih bolj verjetno pride do neželenih učinkov.
English: Concomitant use with agents that are substrates of CYP3A4 (e.g., hormonal contraceptives) may result in increased toxicity or loss of efficacy of these agents.
Slovenian: Sočasna uporaba z učinkovinami, ki so substrati encima CYP3A4 (npr. hormonski kontraceptivi), lahko povzroči povišano toksičnost ali izgubo učinkovitosti teh učinkovin.
English: If you miss a dose of Braftovi, take it as soon as you remember.
Slovenian: Če pozabite vzeti odmerek zdravila Braftovi, ga vzemite takoj, ko se spomnite.
English: How to take Braftovi How much to take
Slovenian: Kako jemati zdravilo Braftovi Koliko zdravila vzeti
English: What Braftovi is and what it is used for 2.
Slovenian: Kaj je zdravilo Braftovi in za kaj ga uporabljamo 2.
English: Usually, these skin changes (see also section 2) are confined to a small area and can be removed with surgery and treatment with Braftovi (and binimetinib) can continue without interruption.
Slovenian: Običajno so te kožne spremembe (glejte tudi poglavje 2) omejene na majhno področje in jih je mogoče kirurško odstraniti, zdravljenje z zdravilom Braftovi (in binimetinibom) pa se lahko neprekinjeno nadaljuje.
English: Neoplasms benign, malignant and unspecified
Slovenian: Benigne, maligne in neopredeljene novotvorbe
English: Pierre Fabre Médicament 45, place Abel Gance 92100 Boulogne-Billancourt France
Slovenian: Pierre Fabre Médicament 45, place Abel Gance 92100 Boulogne-Billancourt Francija
English: An evaluation of change over time in score yielded the same trend for EORTC QLQ-C30 and at all visit for FACT-M.
Slovenian: Ocena spremembe rezultata v določenem obdobju je pokazala enak trend pri vprašalniku EORTC QLQ-C30 in pri vseh obiskih za FACT-M.
English: The accumulation ratio of approximately 0.5 is likely due to auto-induction of CYP3A4.
Slovenian: Razmerje kopičenja približno 0,5 je verjetno posledica samodejne indukcije encima CYP3A4.
English: Mutations in the BRAF gene can produce proteins that cause the melanoma to grow.
Slovenian: Mutacije gena BRAF lahko povzročijo nastanek proteinov, ki povzročijo rast melanoma.
English: • QTcF>500 ms and increased by >60 ms from pre-treatment values
Slovenian: • QTcF > 500 ms in povečanje za > 60 ms glede na vrednosti pred zdravljenjem
English: The median duration of exposure was 11.7 months in patients treated with Combo 450, 7.1 months in patients treated with Enco 300 and 6.2 months in patients treated with vemurafenib.
Slovenian: Mediana trajanja izpostavljenosti je bila 11,7 meseca pri bolnikih, zdravljenih s kombinacijo 450, 7,1 meseca pri bolnikih, zdravljenih z Enko 300, in 6,2 meseca pri bolnikih, zdravljenih z vemurafenibom.
English: Left ventricular dysfunction (LVD)
Slovenian: Disfunkcija levega prekata (LVD)
English: There are no data on the effects of encorafenib on fertility in humans.
Slovenian: Ni podatkov o učinkih enkorafeniba na plodnost pri ljudeh.
English: You should use another reliable method of birth control such as a barrier method (e.g. condom) so you do not become pregnant while you are taking this medicine.
Slovenian: Uporabljati morate dodatno zanesljivo metodo kontracepcije, kot je barierna kontracepcija (npr. kondom), in paziti, da med jemanjem tega zdravila ne zanosite.
English: As a result, no major changes in encorafenib exposure are expected based upon gender.
Slovenian: Zato pri izpostavljanju enkorafenibu niso pričakovane večje spremembe glede na spol.
English: New primary melanoma
Slovenian: Novi primarni melanom
English: There are insufficient data to exclude a clinically significant exposure dependent QT prolongation.
Slovenian: Na voljo ni dovolj podatkov, da bi lahko izključili klinično pomembno podaljšanje intervala QT, ki bi bilo odvisno od izpostavljenosti.
English: a Hazard ratio based on a stratified Cox proportional hazard model b Log-rank p-value (2-sided)
Slovenian: a Razmerje tveganja glede na stratificiran Coxov model sorazmernega tveganja b p-vrednost log-rang testa (2-stranski)
English: • QTcF > 500 ms and change ≤ 60 ms from pre-treatment value
Slovenian: • QTcF > 500 ms in sprememba ≤ 60 ms glede na vrednost pred zdravljenjem
English: • Grade 2 (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3x ≤5x upper limit of normal (ULN))
Slovenian: • 2. stopnja (aspartat aminotransferaza (AST) ali alanin aminotransferaza (ALT) > 3-kratnika-≤ 5kratniku zgornje meje normalne vrednosti (Upper limit of normalULN))
English: You will also receive treatment with another medicine, binimetinib.
Slovenian: Zdravili vas bodo tudi z drugim zdravilom, z binimetinibom.
English: Before starting treatment your doctor will check for the BRAF mutation.
Slovenian: Pred začetkom zdravljenja bo vaš zdravnik preveril, ali imate mutacijo gena BRAF.
English: If you vomit at any time after taking Braftovi, do not take an additional dose.
Slovenian: Če kadar koli po tem, ko ste vzeli zdravilo Braftovi, bruhate, ne vzemite dodatnega odmerka.
English: Updated analysis, cut-off date: 07 November 2017 PFS
Slovenian: Posodobljena analiza, končni datum: 7. november 2017
English: Inhibition of P-gp is unlikely to result in a clinically important increase in encorafenib concentrations as encorafenib exhibits high intrinsic permeability.
Slovenian: Inhibicija P-gp malo verjetno povzroči klinično pomembno povečanje koncentracij enkorafeniba, saj ima enkorafenib visoko intrinzično prepustnost.